Your browser doesn't support javascript.
loading
Consensus and controversies regarding the treatment of rhabdomyosarcoma.
Borinstein, Scott C; Steppan, Diana; Hayashi, Masanori; Loeb, David M; Isakoff, Michael S; Binitie, Odion; Brohl, Andrew S; Bridge, Julia A; Stavas, Mark; Shinohara, Eric T; Meyer, William H; Reed, Damon R; Wagner, Lars M.
Afiliación
  • Borinstein SC; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Steppan D; Division of Pediatric Oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  • Hayashi M; Division of Pediatric Oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  • Loeb DM; Division of Pediatric Oncology, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  • Isakoff MS; Center for Cancer and Blood Disorders, Connecticut Children's Medical Center, Hartford, Connecticut.
  • Binitie O; Sarcoma Department, Adolescent and Young Adult Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Brohl AS; Sarcoma Department, Adolescent and Young Adult Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Bridge JA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.
  • Stavas M; Division of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Shinohara ET; Division of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Meyer WH; Jimmy Everest Section of Pediatric Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Reed DR; Sarcoma Department, Adolescent and Young Adult Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Wagner LM; Division of Pediatric Hematology/Oncology, University of Kentucky, Lexington, Kentucky.
Pediatr Blood Cancer ; 65(2)2018 Feb.
Article en En | MEDLINE | ID: mdl-28905489
Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Rabdomiosarcoma / Algoritmos / Medicina Basada en la Evidencia Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Rabdomiosarcoma / Algoritmos / Medicina Basada en la Evidencia Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2018 Tipo del documento: Article